Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes.

Rosenstock J, Shenouda SK, Bergenstal RM, Buse JB, Glass LC, Heilmann CR, Kwan AY, MacConell LA, Hoogwerf BJ

Diabetes care19 Mar 2012Cited by 54 (Europe PMC)

PMID22432107PMCIDPMC3329851DOI10.2337/dc11-1434PepBankPUB-22432107

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

2 results from studies that gave the peptide. 2 results from people.

01HumanNon-randomized trialEfficacy outcome
In basal insulin-treated diabetes, exenatide reduced A1C more than placebo regardless of baseline A1C.
In plain wordsIn patients using basal insulin, exenatide reduced A1C more than placebo across baseline A1C levels.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseA1C by baseline A1C
Study
n: not reported in source
Comparator
Placebo plus optimized insulin glargine
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Source sentences
Summary
Exenatide participants had greater A1C reductions compared with optimized insulin glargine alone, irrespective of baseline A1C (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Exploratory subgroup analyses based on baseline A1C, disease duration, and BMI of a 30-week study comparing exenatide twice daily to placebo, added to optimized insulin glargine (intent-to-treat analysis: 137 exenatide; 122 placebo).
Report a problemFND-2243210701
02HumanNon-randomized trialEfficacy outcome
In basal insulin-treated diabetes, exenatide reduced weight more than placebo regardless of baseline A1C or BMI.
In plain wordsIn patients using basal insulin, exenatide reduced weight more than placebo across baseline A1C and BMI levels.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight by baseline A1C and BMI
Study
n: not reported in source
Comparator
Placebo plus optimized insulin glargine
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Source sentences
Summary
Exenatide participants lost more weight, regardless of baseline A1C or BMI (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Exploratory subgroup analyses based on baseline A1C, disease duration, and BMI of a 30-week study comparing exenatide twice daily to placebo, added to optimized insulin glargine (intent-to-treat analysis: 137 exenatide; 122 placebo).
Report a problemFND-2243210704

Studies that did not test the peptide alone3

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

03HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
In exenatide-treated diabetes, longer disease duration was associated with greater A1C reductions.
In plain wordsIn patients receiving exenatide, longer diabetes duration was linked to greater A1C reductions than shorter duration.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseA1C by diabetes duration
Study
n: not reported in source
Comparator
Exenatide participants with shorter diabetes duration
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Exenatide participants with longer diabetes duration and those with lower BMI had greater A1C reductions (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
Exploratory subgroup analyses based on baseline A1C, disease duration, and BMI of a 30-week study comparing exenatide twice daily to placebo, added to optimized insulin glargine (intent-to-treat analysis: 137 exenatide; 122 placebo).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2243210702
04HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
In exenatide-treated diabetes, lower BMI was associated with greater A1C reductions.
In plain wordsIn patients receiving exenatide, lower BMI was linked to greater A1C reductions than higher BMI.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseA1C by BMI
Study
n: not reported in source
Comparator
Exenatide participants with higher BMI
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Exenatide participants with longer diabetes duration and those with lower BMI had greater A1C reductions (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
Exploratory subgroup analyses based on baseline A1C, disease duration, and BMI of a 30-week study comparing exenatide twice daily to placebo, added to optimized insulin glargine (intent-to-treat analysis: 137 exenatide; 122 placebo).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2243210703
05HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
In exenatide-treated diabetes, participants with longer disease duration lost the most weight.
In plain wordsIn patients receiving exenatide, longer diabetes duration was linked to greater weight loss than shorter duration.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight by diabetes duration
Study
n: not reported in source
Comparator
Exenatide participants with shorter diabetes duration
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Exenatide participants with longer diabetes duration lost the most weight (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Exploratory subgroup analyses based on baseline A1C, disease duration, and BMI of a 30-week study comparing exenatide twice daily to placebo, added to optimized insulin glargine (intent-to-treat analysis: 137 exenatide; 122 placebo).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2243210705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00765817

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

AstraZenecan = 261Oct 2008 to Jan 2010

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 24 Oct 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.